<DOC>
	<DOC>NCT02222350</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy and safety of DS-8500a compared with placebo in Japanese patients with Type 2 Diabetes Mellitus.</brief_summary>
	<brief_title>Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes</brief_title>
	<detailed_description>The objective of this study is to evaluate the efficacy and safety of DS-8500a 10 mg and 75 mg administered orally, once daily, for 28 days, compared with placebo, in Japanese patients with Type 2 Diabetes Mellitus in a double-blind, placebo-controlled parallel-group design. The primary endpoint is the change in 24-hour weighted mean glucose at day 28 from baseline. The safety, pharmacokinetics, and pharmacodynamics of DS-8500a will be evaluated as well.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Patients aged ≥ 20 years at the time of informed consent Japanese patients with type 2 diabetes Patients who have HbA1c ≥ 7.0% and &lt; 10.0% if untreated with antidiabetic agent. Patients who have HbA1c ≥ 6.5% and &lt; 9.5% if treated with antidiabetic agent. Patients aged ≥ 70 years at the time of informed consent Patients with a history of type 1 diabetes or diabetic ketoacidosis Patients receiving or requiring treatment with insulin Patients with a body mass index (BMI) of &lt; 18.5 kg/m2 or ≥ 35.0 kg/m2 Patients with an estimated glomerular filtration rate (eGFR), &lt; 45 mL/min per 1.73 m2 Patients with fasting plasma glucose ≥ 240 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>